Cyclophosphamide
- Generic Name
- Cyclophosphamide
- Brand Names
- Procytox
- Drug Type
- Small Molecule
- Chemical Formula
- C7H15Cl2N2O2P
- CAS Number
- 50-18-0
- Unique Ingredient Identifier
- 6UXW23996M
- Background
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
- Indication
Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma
- Associated Therapies
- -
Metronomic Low-Dose Cyclophosphamide and Methotrexate With or Without Bevacizumab in Treating Women With Metastatic Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2004-05-17
- Last Posted Date
- 2019-05-21
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 57
- Registration Number
- NCT00083031
- Locations
- 🇺🇸
Massachusetts General Hosptial, Boston, Massachusetts, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Combination Chemotherapy or Observation Following Surgery in Treating Infants With Neuroblastoma
- Conditions
- Neuroblastoma
- First Posted Date
- 2004-05-12
- Last Posted Date
- 2013-12-19
- Lead Sponsor
- Children's Hospital Medical Center, Cincinnati
- Target Recruit Count
- 44
- Registration Number
- NCT00002803
- Locations
- 🇩🇪
University of Cologne, Frechen, Germany
Therapy Based on Stage of Disease and Risk Assessment in Treating Children With Neuroblastoma
- Conditions
- Neuroblastoma
- First Posted Date
- 2004-05-12
- Last Posted Date
- 2013-12-19
- Lead Sponsor
- Children's Hospital Medical Center, Cincinnati
- Target Recruit Count
- 500
- Registration Number
- NCT00002802
- Locations
- 🇩🇪
University of Cologne, Frechen, Germany
High Dose Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Therapy in Treating Women With Locally Recurrent or Metastatic Breast Cancer
- Conditions
- Breast Cancer
- First Posted Date
- 2004-05-12
- Last Posted Date
- 2014-12-16
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 180
- Registration Number
- NCT00002870
- Locations
- 🇫🇷
Centre Paul Papin, Angers, France
🇫🇷Clinique Saint Vincent, Besancon, France
🇫🇷C.H. Bourg En Bresse, Bourg En Bresse, France
High-Dose Chemotherapy Followed by Total-Body Irradiation and Peripheral Stem Cell Transplantation in Treating Patients With Chronic Lymphocytic Leukemia
- Conditions
- Leukemia
- First Posted Date
- 2004-05-11
- Last Posted Date
- 2010-09-15
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 15
- Registration Number
- NCT00002788
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Combination Chemotherapy Plus Surgery and Radiation Therapy in Treating Patients With Ewing's Sarcoma
- Conditions
- Sarcoma
- First Posted Date
- 2004-05-05
- Last Posted Date
- 2013-09-17
- Lead Sponsor
- University Hospital Muenster
- Registration Number
- NCT00002516
- Locations
- 🇬🇧
Royal Victoria Infirmary, Newcastle-upon-Tyne, England, United Kingdom
Rituximab Followed by Combination Chemotherapy in Treating Patients With Refractory or Recurrent Non-Hodgkin's Lymphoma
- Conditions
- Lymphoma
- First Posted Date
- 2004-05-04
- Last Posted Date
- 2021-10-27
- Lead Sponsor
- Medstar Health Research Institute
- Registration Number
- NCT00006669
- Locations
- 🇺🇸
Washington Cancer Institute, Washington, District of Columbia, United States
🇺🇸Franklin Square Hospital Center, Baltimore, Maryland, United States
Standard Chemotherapy Compared With High-Dose Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Women With Advanced or Inflammatory Breast Cancer
- Conditions
- Breast Cancer
- First Posted Date
- 2004-05-03
- Last Posted Date
- 2013-11-06
- Lead Sponsor
- Scottish Cancer Therapy Network
- Target Recruit Count
- 300
- Registration Number
- NCT00003680
- Locations
- 🇬🇧
C.R.C. Beatson Laboratories, Glasgow, Scotland, United Kingdom
Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation
- Conditions
- Cancer
- First Posted Date
- 2004-05-03
- Last Posted Date
- 2012-06-06
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 35
- Registration Number
- NCT00004230
- Locations
- 🇺🇸
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
Bone Marrow Transplantation With Specially Treated Bone Marrow in Treating Patients With Hematologic Cancer That Have Not Responded to Previous Therapy
- Conditions
- Graft Versus Host DiseaseLeukemiaLymphomaMyelodysplastic SyndromesMyeloma
- Interventions
- Drug: cyclophosphamideDrug: cyclosporineDrug: leucovorin calciumDrug: methotrexateDrug: methylprednisoloneProcedure: in vitro-treated bone marrow transplantationRadiation: radiation therapy
- First Posted Date
- 2004-05-03
- Last Posted Date
- 2017-04-04
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 5
- Registration Number
- NCT00005988
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸University of Minnesota Cancer Center, Minneapolis, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.